

Strides Pharma (SA) Proprietary Limited
Balance Sheet as at March 31, 2026

		Amount in ZAR	
	Note No.	31-Mar-26	31-Mar-25
A ASSETS			
I Non-current assets			
(a) Other intangible assets		8,545,371	10,847,005
(b) Intangibles assets under development		1,019,938	944,290
Total non-current assets		9,565,309	11,791,296
II Current assets			
(a) Inventories		32,431,704	92,156,442
(b) Financial assets			
(i) Trade receivables	1	32,736,490	46,508,832
(ii) Cash and cash equivalents	2	8,782,879	4,072
(c) Other Current Assets	3	1,173,238	1,195,921
Total current assets		75,124,311	139,865,268
TOTAL ASSETS		84,689,620	151,656,563
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	4	100	100
(b) Reserves and Surplus	5	(6,206,868)	(16,603,619)
Total Equity		(6,206,768)	(16,603,519)
II Liabilities			
1 Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	6	42,556,166	81,102,924
Total non-current liabilities		42,556,166	81,102,924
2 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	7	42,991,104	84,378,841
(b) Other current liabilities	8	1,908,963	2,653,258
(c) Provisions	9	3,440,155	125,060
Total current liabilities		48,340,222	87,157,159
TOTAL EQUITY AND LIABILITIES		84,689,620	151,656,563

Strides Pharma (SA) Proprietary Limited
Statement of Profit and Loss for the year ended March 31, 2026

Particulars	Note No.	Amount in ZAR	
		31-Mar-26	31-Mar-25
1 Revenue from operations	10	136,309,168	170,738,600
2 Other Income	11	3,191,635	1,118,291
3 Total Revenue (1+2)		139,500,804	171,856,891
4 Expenses			
(a) Cost of material consumed	12	115,957,983	140,523,964
(b) Employee benefits expense	13	87,307	891,577
(c) Finance costs	14	5,575,672	8,748,426
(d) Depreciation and amortisation expense		1,797,661	899,590
(e) Other expenses	15	4,936,827	6,764,310
Total expenses		128,355,449	157,827,867
5 Profit / (Loss) before taxes (3-4)		11,145,355	14,029,024
6 Tax Expense:			
(a) Current tax		748,604	-
Total tax expenses		748,604	-
7 Profit / (Loss) for the year after tax		10,396,751	14,029,024

Strides Pharma (SA) Proprietary Limited
Notes forming part of financial statement

Note No.

1 Trade receivables **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Unsecured		
Considered good	32,736,490	46,508,832
Total	32,736,490	46,508,832

2 Cash and cash equivalents **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Balances with banks:		
In current accounts	8,782,879	4,072
Total	8,782,879	4,072

3 Other current assets **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Unsecured, considered good		
Advances to vendors	-	8,303
Advance tax	936,011	772,116
Prepaid expenses	237,227	415,502
Total	1,173,238	1,195,921

4 Share capital **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Issued, subscribed and fully paid-up		
Equity share capital	100	100
Total	100	100

5 Reserves and surplus **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Securities premium account		
Opening balance	9,267,641	9,267,641
Add : Premium on shares issued during the year	-	-
Closing balance	9,267,641	9,267,641
Surplus in statement of profit and loss		
Opening balance	(25,871,260)	(39,900,284)
Add: Profit / (Loss) for the year	10,396,751	14,029,024
Closing balance	(15,474,509)	(25,871,260)
Total	(6,206,868)	(16,603,619)

Strides Pharma (SA) Proprietary Limited
Notes forming part of financial statement
Note No.

6 Long term borrowings **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Unsecured loan from others	12,197,263	11,271,636
Loan from related Parties	30,358,903	69,831,288
Total	42,556,166	81,102,924

7 Trade payables **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Trade payable	42,991,104	84,378,841
Total	42,991,104	84,378,841

8 Other current liabilities **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Advance received from customer	9,351	2,607
Statutory dues	1,107,051	2,650,651
Others	792,561	-
Total	1,908,963	2,653,258

9 Provisions **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Provision for expenses	3,440,155	125,060
Total	3,440,155	125,060

10 Revenue from operations **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Sale of Product	136,309,168	170,738,600
Total	136,309,168	170,738,600

11 Other Income **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Exchange fluctuation gain	3,191,635	1,118,291
Total	3,191,635	1,118,291

12 Cost of materials consumed **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Opening stock	92,156,442	41,578,881
Add: Purchases	56,233,244	191,101,525
Closing stock	32,431,704	92,156,442
Total	115,957,983	140,523,964

Strides Pharma (SA) Proprietary Limited
Notes forming part of financial statement

Note No.

13 Employee benefit expenses **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Salaries and wages	86,657	881,472
Staff Welfare	650	10,104
Total	87,307	891,577

14 Finance cost **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Bank charges	8,669	7,967
Intra group - finance cost	4,641,407	7,863,747
Interest on term loans	925,596	876,713
Total	5,575,672	8,748,426

15 Other expenses **Amount in ZAR**

Particulars	31-Mar-26	31-Mar-25
Testing and analytical Expenses	-	390,631
Freight and forwarding	4,190,696	4,532,274
Insurance	66,148	158,755
Rates & taxes	1,285,750	380,400
Conveyance & travelling	1,753	473
Advertisement & Selling expenses	75,700	41,665
Provision for doubtful debts	(2,113,984)	-
Net loss on foreign currency transactions	-	-
Professional fees & Legal fees	426,841	251,681
Other Expenses	1,003,922	1,008,431
Total	4,936,827	6,764,310